AssetMark Inc
NBIX icon

AssetMark Inc’s Neurocrine Biosciences NBIX Stock Holding History

AssetMark Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.77M Sell
16,414
-863
-5% -$128K ﹤0.01% 878
2026
Q1 		$2.28M Sell
17,277
-2,044
-11% -$271K ﹤0.01% 857
2025
Q4 		$2.74M Sell
19,321
-915
-5% -$133K 0.01% 781
2025
Q3 		$2.84M Sell
20,236
-765
-4% -$104K 0.01% 738
2025
Q2 		$2.64M Buy
21,001
+2,045
+11% +$235K 0.01% 714
2025
Q1 		$2.1M Sell
18,956
-958
-5% -$121K 0.01% 709
2024
Q4 		$2.72M Buy
19,914
+1,591
+9% +$197K 0.01% 641
2024
Q3 		$2.11M Buy
18,323
+1,753
+11% +$240K 0.01% 642
2024
Q2 		$2.28M Buy
16,570
+4,460
+37% +$612K 0.01% 580
2024
Q1 		$1.67M Sell
12,110
-24,845
-67% -$3.39M 0.01% 619
2023
Q4 		$4.87M Buy
36,955
+8,678
+31% +$999K 0.02% 376
2023
Q3 		$3.18M Buy
28,277
+4,350
+18% +$458K 0.01% 424
2023
Q2 		$2.26M Buy
23,927
+4,151
+21% +$406K 0.01% 455
2023
Q1 		$2M Buy
19,776
+1,903
+11% +$198K 0.01% 451
2022
Q4 		$2.13M Buy
17,873
+1,471
+9% +$172K 0.01% 423
2022
Q3 		$1.74M Buy
16,402
+2,929
+22% +$297K 0.01% 407
2022
Q2 		$1.31M Buy
13,473
+4,317
+47% +$398K 0.01% 435
2022
Q1 		$858K Buy
9,156
+4,093
+81% +$347K ﹤0.01% 502
2021
Q4 		$431K Buy
5,063
+3,585
+243% +$330K ﹤0.01% 568
2021
Q3 		$142K Buy
+1,478
New +$140K ﹤0.01% 612
2019
Q3 		– Sell
-12
Closed -$1K – 1382
2019
Q2 		$1K Buy
12
+2
+20% +$164 ﹤0.01% 1252
2019
Q1 		$1K Sell
10
-18
-64% -$1.5K ﹤0.01% 1261
2018
Q4 		$2K Buy
+28
New +$2.68K ﹤0.01% 1224
2018
Q1 		– Sell
-20
Closed -$2K – 1777
2017
Q4 		$2K Buy
20
+15
+300% +$1.02K ﹤0.01% 1463
2017
Q3 		$0 Buy
+5
New +$264 ﹤0.01% 1568
2016
Q1 		– Sell
-15
Closed -$1K – 1336
2015
Q4 		$1K Buy
+15
New +$762 ﹤0.01% 1233

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

AssetMark Inc's NBIX Position: Q2 2026 in Review

AssetMark Inc reduced its Neurocrine Biosciences (NBIX) stake by 5% in Q2 2026, selling an estimated $128K and leaving 16,414 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #878.

AssetMark Inc first reported a position in NBIX in Q4 2015 and has held it in 26 quarters since. The position peaked at $4.87M in Q4 2023. 260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • AssetMark Inc held 16,414 shares of Neurocrine Biosciences worth $2.77M as of Q2 2026.
  • AssetMark Inc sold 863 Neurocrine Biosciences shares in Q2 2026, an estimated $128K.
  • Neurocrine Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #878 holding.
  • AssetMark Inc first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 26 quarters since.
  • AssetMark Inc's Neurocrine Biosciences position peaked at $4.87M in Q4 2023.
  • 260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.